The influence of an angiotensin II antagonist, saralasin, given before donor nephrectomy, on kidney function after transplantation. A controlled prospective study.
Kidneys from cadaver donors who had been treated during the last 10 min before bilateral nephrectomy with an infusion of 10 micrograms/kg-1/min-1 (Sar1, Val5, Ala8)-angiotensin II had a remarkable, significantly lower percentage of acute renal failure (25%) after renal transplantation than untreated kidneys (58.3%). Anuria was seen in the treated group only in 4.2%, although it occurred in the untreated control group in 16.6%. The role of the activated renin-angiotensin system in postischemic acute renal failure is discussed.
D058186:Acute Kidney Injury / Q000517:prevention & control; D000293:Adolescent; D000328:Adult; D000804:Angiotensin II / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors; D002648:Child; D004231:Diuresis / Q000187:drug effects; D005260:Female; D006801:Humans; D007511:Ischemia / Q000209:etiology / Q000517:prevention & control; D007668:Kidney / Q000098:blood supply / Q000502:physiology; D016030:Kidney Transplantation; D008297:Male; D009392:Nephrectomy / Q000009:adverse effects; D011446:Prospective Studies; D012504:Saralasin / Q000494:pharmacology*
D000804:Angiotensin II; D012504:Saralasin